Institute for Molecular Medicine Finland | GenomeWeb

Institute for Molecular Medicine Finland

The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio. 

NEW YORK (GenomeWeb News) – Studies by two independent research teams published online yesterday in Nature Neuroscience suggest a single gene — the enzyme-coding gene called TOP3B — contributes to processes related to schizophrenia and to a syndrome associated with autism spectrum disord

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

The program will consist of miniaturized RNAi screens, and in the future will include compound/drug arrays.

FIMM studies cancer, as well as cardiovascular, neuro-psychiatric and viral diseases, carries out translational research, and seeks to promote human health through research on personalized medicine.

The Nordic nation will invest in a pan-European pilot program for cultivating informatics, biobanking, and translational research.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.